These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 32981193

  • 1. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
    D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, Shariat SF.
    BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
    [Abstract] [Full Text] [Related]

  • 2. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
    Zennami K, Sumitomo M, Takahara K, Nukaya T, Takenaka M, Fukaya K, Ichino M, Fukami N, Sasaki H, Kusaka M, Shiroki R.
    BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
    [Abstract] [Full Text] [Related]

  • 3. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
    Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J, Collaborators.
    J Urol; 2020 Apr; 203(4):690-698. PubMed ID: 31702432
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
    Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W, Collaborators.
    J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH.
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.
    Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, Briganti A, Muilwijk T, Hendricksen K, Lotan Y, Karakiewic P, F Shariat S, UTUC collaboration.
    World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726
    [Abstract] [Full Text] [Related]

  • 11. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
    Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, Rouprêt M, Boorjian SA, Potretzke AM, Roshandel MR, Ploussard G, Djaladat H, Ghoreifi A, Mari A, Campi R, Khene ZE, Raman JD, Kikuchi E, Rink M, Abdollah F, Boormans JL, Fujita K, D'Andrea D, Soria F, Breda A, Hoffman-Censits J, McConkey DJ, Shariat SF, Pradere B, Singla N.
    Eur Urol Oncol; 2024 Oct; 7(5):1061-1068. PubMed ID: 38262800
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study.
    Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, Shariat SF.
    Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303
    [Abstract] [Full Text] [Related]

  • 13. Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
    Amini E, Ahmadi N, Clifford TG, Hugen CM, Bazargani ST, Cai J, Miranda G, Sherrod AE, Daneshmand S, Djaladat H.
    Int Urol Nephrol; 2019 Mar; 51(3):435-441. PubMed ID: 30706249
    [Abstract] [Full Text] [Related]

  • 14. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP.
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
    Cancer; 2015 Aug 01; 121(15):2586-93. PubMed ID: 25872978
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.
    Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF, European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group.
    BJU Int; 2018 Feb 01; 121(2):252-259. PubMed ID: 28940605
    [Abstract] [Full Text] [Related]

  • 17. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC.
    Eur Urol; 2015 Feb 01; 67(2):241-9. PubMed ID: 25257030
    [Abstract] [Full Text] [Related]

  • 18. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, Izawa M, Baba Y, Sanjo T, Shojo K, Tanaka N, Takeda T, Kosaka T, Mizuno R, Mikami S, Kikuchi E, Oya M.
    Cancer Sci; 2021 Mar 01; 112(3):1084-1094. PubMed ID: 33368857
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
    Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J.
    Eur Urol; 2021 May 01; 79(5):635-654. PubMed ID: 32798146
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
    Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC.
    Urol Oncol; 2013 Nov 01; 31(8):1737-43. PubMed ID: 23141776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.